Abstract
Anaplastic lymphoma kinase (ALK) has been recognised as a promising molecular target of targeted therapy for NSCLC. We performed SAR study of pyrazolo[3,4-b]pyridines to override crizotinib resistance caused by ALK-L1196M mutation and identified a novel and potent L1196M inhibitor, 10g. 10g displayed exceptional enzymatic activities (<0.5 nM of IC50) against ALK-L1196M as well as against ALK-wt. In addition, 10g is an extremely potent inhibitor of ROS1 (<0.5 nM of IC50) and displays excellent selectivity over c-Met. Moreover, 10g strongly suppresses proliferation of ALK-L1196M-Ba/F3 and H2228 cells harbouring EML4-ALK via apoptosis and the ALK signalling blockade. The results of molecular docking studies reveal that, in contrast to crizotinib, 10g engages in a favourable interaction with M1196 in the kinase domain of ALK-L1196M and hydrogen bonding with K1150 and E1210. This SAR study has provided a useful insight into the design of novel and potent inhibitors against ALK gatekeeper mutant.
Original language | English |
---|---|
Pages (from-to) | 1426-1438 |
Number of pages | 13 |
Journal | Journal of Enzyme Inhibition and Medicinal Chemistry |
Volume | 34 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- ALK-L1196M mutant
- Anaplastic lymphoma kinase
- pyrazolopyridine-based inhibitor
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery